Compare Salesforce Inc (CRM) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Eli Lilly And Co — how do they compare? Salesforce Inc trades at $229.19 (market cap $187.48B), while Eli Lilly And Co trades at $1,176.57 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 5.5× Salesforce Inc's market cap, and Salesforce Inc pays the higher dividend (0.77%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Eli Lilly And Co for 93 Days on average.
| CRM | LLY | |
|---|---|---|
Market Cap | $187.48B | $1.04T |
Volume | 6,155,822 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $266.23 | $1.28K |
52-Week Low | $150.12 | $799.57 |
Typical Hold Time | 89 Days | 93 Days |
Enterprise Value | $217.82B | $1.09T |
Dividend Yield | 0.77% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $228.19, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 77.3% gross margins and 22% net income margin. Recent news highlights AI-driven growth potential despite sector-wide software stock volatility. Analyst consensus remains strongly bullish with a $271.91 price target, representing 19% upside potential from current levels.
CRM presents a compelling opportunity with strong profitability and AI monetization driving growth, though technical weakness and sector headwinds pose near-term risks. The company's rule of 44 performance and expanding free cash flow support long-term upside, but investors should monitor competitive pressures and macroeconomic conditions affecting software valuations.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
